FSS icon
  • WHY FSS?
    • About Us
    • Careers
  • SERVICES
    • Data Management
    • Biostatistics
    • Quality
    • Monitoring
  • OUTREACH
    • Patient
    • STEM
    • Inclusivity and Sustainability
    • Community
  • RESOURCES
    • FSS News
    • Case Studies
    • Projects
    • Publications
    • Insights
    • NeoALTTO & ALTTO Research Projects
  • CONTACT US
The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

by Robin McConnell | Sep 1, 2014 | NeoALTTO, Publications

OVERVIEW Reported data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response the the Neo-ALTTO trial. STUDY DETAILS The Neo-ALTTO (Neoadjuvant Lapatinib and/or...
The HERA Trial: Cardiac Events at 8 years median follow-up

The HERA Trial: Cardiac Events at 8 years median follow-up

by Dewi Owens | Jul 10, 2014 | HERA, Publications

TITLE OF PUBLICATION Trastuzumab-associated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant Trial (HERA BIG 1-01) AUTHORS Evandro de Azambuja, Marion J. Procter, Dirk J. van Veldhuisen, Dominique Agbor-Tarh, Otto Metzger-Filho, Jutta...
The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

by Dewi Owens | Feb 18, 2012 | NeoALTTO, Publications

OVERVIEW An argument that the two anti-HER2 agents, trastuzumab and lapatinib, given together would be better than single-agent therapy. STUDY DETAILS The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter...
The HERA Trial: Cardiac Events at 8 years median follow-up

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

by Dewi Owens | Jun 20, 2009 | HERA, Publications

TITLE OF PUBLICATION Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial AUTHORS Mitch Dowsett, Marion Procter, Worta McCaskill-Stevens, Evandro de...
The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

by Dewi Owens | Jun 1, 2008 | HERA, Publications

OVERVIEW An assessment of the magnitude of the clinical benefits of trastuzumab for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study. TITLE OF PUBLICATION Estimating the magnitude of trastuzumab...
The HERA Trial: Results of the First Planned Interim Analysis

The HERA Trial: Results of the First Planned Interim Analysis

by Dewi Owens | Oct 20, 2005 | HERA, Publications

OVERVIEW The New England Journal of Medicine reports the results, at the first planned interim analysis (median follow-up of one year), only of treatment with trastuzumab for one year or observation.  The Herceptin Adjuvant (HERA) (Breast International Group [BIG]...
Next Entries »

Recent Posts

  • NordICC | The Lancet
  • Making Sense of Medical Research
  • APHINITY | Journal of the National Cancer Institute
  • FLAIR | British Journal of Haematology
  • COLONIZE | Annals of Internal Medicine

Recent Comments

No comments to show.


Data Protection

EU Representative

Privacy

Cookies

CONTACT US
LinkedIn Logo

Frontier Science (Scotland) Ltd © 2022
Scottish Charity: SCO33112 | Scottish Company: SC220936

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}